Mundipharma and Purdue reach a new deal to in-licence from ESTEVE full global rights and development responsibilities for novel first-in-class sigma-1 antagonist (S1A or MR309/E-52862)
Mundipharma Medical Company Limited and its independent associated company, Purdue Pharma L.P., today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Laboratorios Esteve, S.A.U. (ESTEVE) for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist (S1A or MR309/E-52862).
Mundipharma and ESTEVE recognise that the problem of pain is not solved and are committed to developing new treatments to help patients better manage their pain. The addition of this asset to the Mundipharma pain pipeline continues the growth of the global pain franchise, an area of deep heritage and experience for the Mundipharma network of independent associated companies worldwide.
MR309/E-52862 is a potent and highly selective sigma-1 antagonist that may provide a new way to approach the management of neuropathic pain, one of the most challenging pain conditions to manage.
Studies suggest that the novel mechanism of action of MR309/E-52862 will be complementary to those of other drugs used in pain management and may therefore support combination usage with other analgesic compounds. Furthermore, it offers the potential for improvement over current therapeutic options, as many currently available treatments for pain are associated with troublesome side effects, limited efficacy, frequent dosing and/or titration.
MR309/E-52862 binds to sigma-1 in the brain and central nervous system. To date, activity has been demonstrated in vitro and in vivo in multiple models of neuropathic pain, including nerve injury and diabetic neuropathy. These studies have also proven that there is a direct relationship between dose, target occupancy of MR309/E-52862 in the brain and pharmacological activity.1
In the Phase I programme, in which human subjects were administered MR309/E-52862, good safety, tolerability, pharmacodynamic and pharmacokinetic profiles were observed at all doses tested.2,3
Phase II clinical studies on patients treated with MR309/E-52862 in peripheral neuropathy of different aetiologies (including from diabetic and post-surgical origins) as well as in moderate to severe acute post-operative pain have been conducted and the results are pending publication. Mundipharma will now take the programme forward into additional clinical studies to support the ongoing development in multiple models of neuropathy and future registration and commercialisation.
Antony Mattessich, Managing Director, Mundipharma International Limited commented on the partnership. “We’re very excited about the opportunity to realise the potential of MR309/E-52862 to help patients and healthcare professionals manage neuropathic pain in an area of high unmet need. MR309/E-52862 will form a key part of our growing pain pipeline, and will add to our heritage and leadership in the area. We’re also thrilled to expand our partnership with ESTEVE. This strategic collaboration leverages our companies’ individual strengths. Our ability to bring products through the clinical and regulatory process and to successfully commercialise them complements ESTEVE’s focus on discovering novel approaches to the treatment of pain in the laboratory. Mundipharma, Purdue and ESTEVE are equally committed to driving innovation in pain management, so our ongoing collaboration is a natural fit.”
Albert Esteve, Chief Executive Officer, ESTEVE, said: “This partnership with Mundipharma will, we hope, allow patients to have access to a new class of treatment to manage pain. Together, we will foster the development of a first-in-class new molecular entity targeting a novel mechanism of action for pain relief. The alliance with Mundipharma and Purdue strengthens the validation of our innovative first-in-class NME R&D and our mission statement, which is to advance science by establishing novel R&D collaborations and to solve unmet medical needs of diseases with significant social impact.”
Mundipharma and its independent associated companies are privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of significant new treatment options in the core therapy areas of pain, respiratory, oncology and inflammatory conditions. Through innovation, design and acquisition, Mundipharma and its independent associated companies deliver important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide. For further information please visit: www.mundipharma.com
ESTEVE is a leading pharmaceutical chemical group based in Barcelona, Spain. Since it was founded in 1929, ESTEVE has been firmly committed to excellence in healthcare, dedicating efforts to innovative R&D of new medicines for unmet medical needs and focusing on high science and evidence-based research. ESTEVE has a strong partnership approach to drug discovery, development and commercialisation. The company works both independently and in collaboration to bring new, differentiated best-in-class treatments to patients who need them. The company currently employs 2,300 professionals and has subsidiaries and production facilities in several European countries, USA, China and Mexico. More about ESTEVE at www.esteve.com and www.esteve.com/research-development
1 Romero L, et al. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. British Journal of Pharmacology. 2012;166(8):2289-2306.
2 Abadias M, et al. Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies. British Journal of Clinical Pharmacology. 2012;75(1):103-117.
3 Täubel J, et al. Single doses up to 800 mg of E-52862 do not prolong the QTc interval--A retrospective validation by pharmacokinetic-pharmacodynamic modelling of electrocardiography data utilising the effects of a meal on QTc to demonstrate ECG assay sensitivity. PLoS One. 2015;10(8):e0136369.
May 2016 MINT/MPAIN-16011
Mundipharma International Limited
Corporate Communications Lead
T: +44 (0) 1223 397 162
T: +44 (0) 207 067 0180
Corporate Communications Head
T: +34 93 446 62 60
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Kymeta Announces Commercial Availability of KĀLO™ Mobile Internet Access Services14.12.2017 15:00 | Pressemelding
Kymeta—the communications company making good on the promise of global, mobile connectivity—and Intelsat S.A. (NYSE:I)—operator of the world’s first globalized network—have announced that Kymeta KĀLO internet access is now available with broad initial geographic coverage. Kymeta is redefining how satellite services are purchased with KĀLO internet services, and making mobile communications as easy to buy as a mobile phone plan. KĀLO internet services, powered by the IntelsatOne® Flex network, deliver broad connectivity when paired with the world’s only commercially available flat panel, electronically-steered satellite terminals from Kymeta as well as other satellite terminal solutions. Kymeta™ KyWay™ terminals and mTennau7 antenna subsystem modules open new markets for the satellite industry and allow organizations that require high-bandwidth mobile internet access to do busine
BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion14.12.2017 13:47 | Pressemelding
BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease. BioVectra Inc. brings over 45 years of contract development and manufacturing experience to the partnership, including working with Keryx to manufacture Ferric Citrate API since 2003. BioVectra will prepare for the anticipated growth in the long-term Ferric Citrate API supply needs by expanding production capacity at their headquarters facility in Charlottetown, PEI, Canada. “This partnership is a pivotal step in our journey as BioVectra. It is a shining example of the innovation, talent and determination we have
DoubleTree by Hilton Closes Out Milestone Year with 30+ New Hotels, 510 Hotels Worldwide14.12.2017 13:01 | Pressemelding
2017 was a monumental year for DoubleTree by Hilton, one of Hilton’s (NYSE: HLT) 14 market-leading brands, surpassing 500 hotels worldwide and introducing 30+ new hotels to guests around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171214005385/en/ DoubleTree by Hilton Dubai - Business Bay (Photo: DoubleTree by Hilton) To close out the year, the brand recently welcomed an additional three hotels to its portfolio. With convenient locations, inspired design and thoughtful upscale amenities, these hotels are now delivering unparalleled hospitality to guests and visitors, all starting with the brand’s signature, warm DoubleTree Cookie welcome. DoubleTree by Hilton Neenah : This contemporary hotel, which recently completed a multimillion
Dole Pineapple Workers Open Community Center Thanks to Fair Trade14.12.2017 13:00 | Pressemelding
Dole Food Company and Fair Trade USA jointly announced today the inauguration of two new community centers near Dole’s Muelle and Bosque Farms in Costa Rica, made possible by Fair Trade purchases made at Whole Foods Market stores, which drive additional money to pineapple farmworkers to invest in projects of their choosing. The commencement events at the two locations took place on December 5th and 6th, 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171214005458/en/ (Photo: Business Wire) To earn Fair Trade certification, farms must adhere to rigorous social, environmental and economic standards. Once certified, farmworkers directly earn additional Community Development Funds with every purchase. They then vote on how to use the money to address their needs. This direct economic be
Reply: Go Reply Becomes a Google Cloud Managed Service Provider14.12.2017 13:00 | Pressemelding
Go Reply, the Reply Group company specialising in innovative Cloud services based on Google Cloud technology, has become a Google Cloud Managed Service Provider (MSP), joining a group of highly specialized Google Cloud partners. Go Reply supports customers through the whole cloud journey, able to respond to business needs during the different phases of the process, from engagement, to migration and execution, to post planning with optimization after deployment. As a Google Cloud MSP, Go Reply provides a high-touch service to customers who are looking for a complete and proactive support. Go Reply is able to bundle exclusive services for enterprise customers, covering not only the Cloud migration, but also all the aspects of the process, including future developments. Go Reply has access to Google training programs, Google Professional Services, and Google S
21st Century Fox to Spin off Businesses and Create New “Fox”; a Growth Company Centered on Live News and Sports Brands and the Iconic Fox Brand14.12.2017 12:12 | Pressemelding
Twenty-First Century Fox, Inc. (“21st Century Fox” or the “Company” – NASDAQ: FOXA, FOX) today announced that it intends to spin off to 21st Century Fox shareholders a portfolio of its highly-rated news, sports and broadcast businesses to create a new “Fox,” which will be a growth company centered on live news and sports brands, anchored by the strength of the Fox Network. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171214005660/en/ Left to right: Robert A. Iger, Chairman and CEO of The Walt Disney Company, and Rupert Murdoch, Executive Chairman, 21st Century Fox (Photo: Business Wire) The new “Fox” will include iconic branded properties Fox News Channel, Fox Business Network, Fox Broadcasting Company, Fox Sports, Fox Television Stations Group, and sports cable networks FS1, FS2, Fox Deportes and B
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom